年赚35.7亿元的京东健康，却还是摆脱不了"互联网大药房"的标签。日前，京东健康发布了2025年上半年业绩报告，GPLP犀牛财经注意到，在这份财报 中，收入、盈利以及毛利等多重核心指标上，都体现出了京东健康的增长韧性。 从业务构成来看，2025上半年，京东健康医药和健康产品销售贡献收入293亿元，同比增长22.7%；线上平台、数字化营销及其他服务贡献收入60亿元，同 比增长34.4%。 京东健康营销上的投入同样水涨船高。2025年上半年，京东健康销售及市场推广开支为18亿元，同比增长28.8%，主要因推广及广告开支增加及提供的技术 和流量支持服务开支增加。 2025年上半年，京东健康收入为352.90亿元，同比增长24.5%；非国际财务报告准则下的盈利为35.7亿元，同比增长35.0%；毛利为88.92亿元，同比增长 32.7%。 | | 截至6月30日止六個月 | | | | --- | --- | --- | --- | | | 2025年 | 2024年 | 同比變動 | | | 人民幣千元 | 人民幣千元 | (%) | | | (未經審計) | (未經審計) | | | 收入 | 35,290,04 ...

Group 1: Market Performance - The CSI Hong Kong Stock Connect Medical Theme Index (932069) has risen by 2.27% as of August 18, 2025, with notable increases in constituent stocks such as JD Health (06618) up 9.88% and Yiyang Sunshine (02522) up 8.90% [1] - The Hong Kong Medical ETF (159366) has increased by 1.93%, reaching a latest price of 1.64 HKD, and has seen a cumulative increase of 8.71% over the past week as of August 15, 2025 [1] - The average daily trading volume of the Hong Kong Medical ETF over the past month is 311 million HKD, with the latest fund size reaching a record high of 2.93 billion HKD [1] Group 2: Company Performance - JD Health reported a 22.7% year-on-year increase in sales revenue for pharmaceuticals and health products, reaching 29.3 billion HKD in the first half of 2025, driven by an increase in annual purchasing users exceeding 200 million and higher average spending per user [2] - The platform, advertising, and other service revenues for JD Health grew by 34.4% to 5.96 billion HKD, attributed to sustained growth in advertising revenue and an expanding commission scale supported by transaction growth [2] - JD Health launched over 30 innovative drugs online in the first half of 2025 and has seen a significant increase in the number of merchants on its platform, exceeding 150,000 compared to over 100,000 at the end of 2024 [2] Group 3: Industry Trends - The global AI medical investment and financing landscape is thriving, with significant breakthroughs in AI medical research, including FDA approval for the first AI wearable treatment device and advancements in AI drug development [3] - The Hong Kong Medical ETF (159366) is noted for having the highest CXO content in the market, focusing on internet medical services, CXO, and medical devices, and closely tracks the CSI Hong Kong Stock Connect Medical Theme Index [3] - The CSI Hong Kong Stock Connect Medical Theme Index includes 50 listed companies involved in medical devices, medical services, and pharmaceutical sectors, reflecting the overall performance of the medical sector within the Hong Kong Stock Connect [3] Group 4: Index Composition - As of June 30, 2025, the top ten weighted stocks in the CSI Hong Kong Stock Connect Medical Theme Index include WuXi Biologics (02269) at 14.58% and JD Health (06618) at 10.83%, collectively accounting for 56.9% of the index [4]

Core Insights - JD Health's stock rose over 10% following the release of its interim results, with a current price of HKD 60.7 and a trading volume of HKD 2.19 billion [1] Financial Performance - For the six months ending June 30, 2025, JD Health reported revenue of RMB 35.29 billion, a year-on-year increase of 24.5% [1] - Non-IFRS profit for the same period was RMB 3.57 billion, up 35% year-on-year [1] - Net profit attributable to shareholders was RMB 2.596 billion, reflecting a 27.45% increase year-on-year [1] - Basic earnings per share were RMB 0.82 [1] Revenue Breakdown - Revenue for the three months ending June 30, 2025, increased by 23.7% to RMB 18.6 billion compared to the previous year [1] - Revenue from the sale of pharmaceutical and health products rose from RMB 23.9 billion to RMB 29.3 billion, marking a 22.7% increase [1] - Growth in product revenue was driven by an increase in active user numbers, additional purchases by users, higher online penetration rates for pharmaceutical and health products, and a wider range of product categories [1] Service Revenue Growth - Service revenue from online platforms and digital marketing increased by 34.4%, from RMB 4.4 billion to RMB 6 billion [2] - The growth in service revenue was primarily due to an increase in digital marketing service fees, attributed to a rise in the number of advertisers on the platform and consistent growth in transactions [2]